Supriya Lifescience targets ₹1000 crore revenue by FY27 following 52% Q4 growth

Market snapshot: Supriya Lifescience has set an ambitious revenue target of over ₹1,000 crore for FY27, coming on the heels of a powerful Q4 FY26 performance. The Mumbai-headquartered API specialist is leveraging aggressive capacity expansion and a shift toward high-margin niche therapeutic segments to drive its next phase of growth.

Data Snapshot

• FY26 Revenue: ₹827.87 crore (+18.86% YoY)
• Q4 FY26 Revenue: ₹280 crore (+52.17% YoY)
• FY26 Net Profit: ₹209.12 crore (+11.26% YoY)
• EBITDA Margin: 35.30% in Q4 FY26
• Capacity Utilization: Increased from 70% to 78% in FY26

What's Changed

• Revenue baseline moved from ₹706 crore (FY25) to ₹828 crore (FY26), reducing the required growth for the ₹1,000 crore target to approximately 21%.
• The Lote Parshuram facility capacity increased by 55% to 932 KLPD following the commissioning of Module E.
• Shift in product mix: Anaesthetics now contribute over 50% of total revenue, driving absolute EBITDA growth despite minor margin pressure.

Key Takeaways

• Targeting ₹1,000 crore revenue in FY27 is feasible given the 19% CAGR required from the current FY26 base.
• Ambernath formulation facility is expected to contribute full-year commercial revenue starting in FY27.
• Debt-free status remains a core financial pillar, with all expansion funded via internal accruals.

SAHI Perspective

Supriya Lifescience is evolving from a pure API player into a diversified pharmaceutical entity with a growing focus on CDMO and finished dosages. The successful ramp-up of the Module E facility at Lote Parshuram and the entry into regulated markets with 3–4 new product launches annually provide the necessary tailwinds to hit the ₹1,000 crore milestone. The company's 74% backward integration provides a resilient margin buffer against global supply chain volatility.

Market Implications

The API sector is witnessing a consolidation of market share among players with high backward integration. Supriya's growth signal suggests a robust recovery in regulated market demand, particularly for anaesthetics and anti-histamines. For capital allocation, this indicates a shift toward companies with clear capacity visibility and debt-free balance sheets in the mid-cap pharma space.

Trading Signals

Market Bias: Bullish

The 52% Q4 revenue surge and FY27 revenue guidance of ₹1,000 crore suggest high growth visibility, backed by a debt-free balance sheet and 35%+ EBITDA margins.

Overweight: Pharma API, CDMO, Specialty Chemicals

Underweight: Bulk Generic Exporters (High China Dependence)

Trigger Factors:

• Ambernath facility reaching EBITDA positivity in Q3 FY27
• USFDA inspection outcomes for the Patalganga site
• Successful launch of 3-4 new molecules in the anaesthetic segment

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian API industry is currently benefiting from the 'China Plus One' strategy, with global innovators seeking reliable supply partners. Supriya's focus on high-margin anaesthetics and its move toward 82% backward integration aligns with the industry trend of value-chain climbing to sustain double-digit growth.

Key Risks to Watch

• Raw material price volatility for non-integrated products.
• Regulatory risks associated with USFDA and European audits of new facilities.
• Concentration risk, as anaesthetics currently account for over 50% of revenue.

Recent Developments

In May 2026, Supriya Lifescience reported a consolidated revenue of ₹827.87 crore for FY26, alongside a recommended dividend of ₹1.00 per share. The company successfully commissioned its 335 KL Module E block at Lote Parshuram in late 2025, which has been instrumental in the recent revenue surge. Additionally, the Ambernath formulation facility began commercial operations in Q4 FY26.

Closing Insight

With a clear roadmap to ₹1,000 crore and a proven ability to scale without taking on debt, Supriya Lifescience is positioning itself as a high-performance contender in the Indian API and CDMO landscape.

FAQs

Is the ₹1,000 crore revenue target for FY27 realistic?

Yes, following the FY26 revenue of ₹827.87 crore, the company requires approximately 21% growth to hit the target, which is consistent with its current 5-year CAGR and recent 52% Q4 growth.

How does backward integration benefit Supriya Lifescience?

Currently at 74% and targeting 82%, backward integration allows the company to sustain EBITDA margins of 33-35% even during periods of product mix shifts or rising operational costs.

What is the status of the company's debt?

Supriya Lifescience remains a debt-free company, funding its recent ₹160 crore Ambernath expansion and upcoming Patalganga capex entirely through internal accruals.

High Performance Trading with SAHI.